TEVA – Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries TEVA
$34.31Name : Teva Pharmaceutical Industries
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $39,958,757,376.00
EPSttm : 1.21
Teva Pharmaceutical Industries
$34.31
0.17%$0.06Float Short %
3.31
Margin Of Safety %
-13
Put/Call OI Ratio
0.59
EPS Next Q Diff
-0.27
EPS Last/This Y
1.45
EPS This/Next Y
0.41
Price
34.29
Target Price
39.11
Analyst Recom
1.43
Performance Q
41.43
Relative Volume
0.52
Beta
0.72
Ticker: TEVA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-13 | TEVA | 32.49 | 0.63 | 0.99 | 603985 |
| 2026-01-14 | TEVA | 32.65 | 0.64 | 0.66 | 608800 |
| 2026-01-15 | TEVA | 32.35 | 0.66 | 0.21 | 623051 |
| 2026-01-16 | TEVA | 31.76 | 0.66 | 0.36 | 628392 |
| 2026-01-20 | TEVA | 31.35 | 0.60 | 0.21 | 415077 |
| 2026-01-21 | TEVA | 31.42 | 0.60 | 2.22 | 415715 |
| 2026-01-22 | TEVA | 31.66 | 0.57 | 0.27 | 404711 |
| 2026-01-23 | TEVA | 31.83 | 0.57 | 0.22 | 403815 |
| 2026-01-26 | TEVA | 32.14 | 0.57 | 0.65 | 401739 |
| 2026-01-27 | TEVA | 32.53 | 0.57 | 0.30 | 405200 |
| 2026-01-28 | TEVA | 33.22 | 0.56 | 0.38 | 416892 |
| 2026-01-29 | TEVA | 33.06 | 0.56 | 0.42 | 424568 |
| 2026-01-30 | TEVA | 34.1 | 0.56 | 0.12 | 427521 |
| 2026-02-02 | TEVA | 35.53 | 0.55 | 0.34 | 425023 |
| 2026-02-03 | TEVA | 36.24 | 0.57 | 0.29 | 431195 |
| 2026-02-05 | TEVA | 34.78 | 0.58 | 0.55 | 435436 |
| 2026-02-09 | TEVA | 34.47 | 0.58 | 0.67 | 425729 |
| 2026-02-10 | TEVA | 34.37 | 0.58 | 0.14 | 425130 |
| 2026-02-11 | TEVA | 34.28 | 0.59 | 0.49 | 426418 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-13 | TEVA | 32.48 | -10.0 | 376.5 | 2.64 |
| 2026-01-14 | TEVA | 32.64 | -10.0 | 421.3 | 2.64 |
| 2026-01-15 | TEVA | 32.35 | -10.0 | 399.6 | 2.64 |
| 2026-01-16 | TEVA | 31.77 | -10.0 | 383.2 | 2.64 |
| 2026-01-20 | TEVA | 31.34 | -10.0 | 356.0 | 2.64 |
| 2026-01-21 | TEVA | 31.43 | -10.0 | 396.1 | 2.64 |
| 2026-01-22 | TEVA | 31.66 | -10.0 | 405.7 | 2.64 |
| 2026-01-23 | TEVA | 31.82 | -10.0 | 419.9 | 2.64 |
| 2026-01-26 | TEVA | 32.14 | -10.0 | 422.4 | 2.64 |
| 2026-01-27 | TEVA | 32.54 | -10.0 | 449.6 | 2.64 |
| 2026-01-28 | TEVA | 33.19 | -10.0 | 465.4 | 2.64 |
| 2026-01-29 | TEVA | 33.05 | -10.0 | 524.7 | 2.64 |
| 2026-01-30 | TEVA | 34.10 | 15.0 | 435.4 | 2.77 |
| 2026-02-02 | TEVA | 35.53 | 15.0 | 583.3 | 2.77 |
| 2026-02-03 | TEVA | 36.24 | 5.6 | 498.3 | 2.67 |
| 2026-02-04 | TEVA | 34.95 | 5.6 | 391.0 | 2.67 |
| 2026-02-05 | TEVA | 34.79 | 5.6 | 74.0 | 2.68 |
| 2026-02-06 | TEVA | 34.66 | 5.6 | 75.4 | 2.68 |
| 2026-02-09 | TEVA | 34.47 | 5.6 | 148.1 | 2.68 |
| 2026-02-10 | TEVA | 34.36 | 5.6 | 162.9 | 2.68 |
| 2026-02-11 | TEVA | 34.29 | 5.6 | 125.6 | 2.68 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-13 | TEVA | -30.37 | -4.66 | 2.87 |
| 2026-01-14 | TEVA | -30.37 | -4.66 | 2.87 |
| 2026-01-15 | TEVA | -30.37 | -4.66 | 2.87 |
| 2026-01-16 | TEVA | -30.37 | -4.66 | 2.87 |
| 2026-01-20 | TEVA | -30.37 | -4.95 | 2.87 |
| 2026-01-21 | TEVA | -30.37 | -4.95 | 2.87 |
| 2026-01-22 | TEVA | -30.37 | -4.95 | 2.87 |
| 2026-01-23 | TEVA | -30.37 | -4.95 | 2.87 |
| 2026-01-26 | TEVA | -30.37 | -4.39 | 2.87 |
| 2026-01-27 | TEVA | -30.37 | -4.39 | 2.87 |
| 2026-01-28 | TEVA | -30.37 | -4.39 | 2.88 |
| 2026-01-29 | TEVA | -30.37 | -4.39 | 2.88 |
| 2026-01-30 | TEVA | -30.37 | -4.39 | 2.88 |
| 2026-02-02 | TEVA | -30.37 | -4.44 | 2.88 |
| 2026-02-03 | TEVA | -30.37 | -4.44 | 2.88 |
| 2026-02-04 | TEVA | -30.37 | -4.44 | 2.88 |
| 2026-02-05 | TEVA | -30.37 | -4.44 | 2.88 |
| 2026-02-06 | TEVA | -28.78 | -4.44 | 2.88 |
| 2026-02-09 | TEVA | -28.78 | -3.99 | 2.88 |
| 2026-02-10 | TEVA | -28.78 | -3.99 | 2.88 |
| 2026-02-11 | TEVA | -28.78 | -3.99 | 3.31 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.93
Avg. EPS Est. Current Quarter
0.55
Avg. EPS Est. Next Quarter
0.66
Insider Transactions
-28.78
Institutional Transactions
-3.99
Beta
0.72
Average Sales Estimate Current Quarter
3872
Average Sales Estimate Next Quarter
4126
Fair Value
29.76
Quality Score
70
Growth Score
47
Sentiment Score
76
Actual DrawDown %
8.2
Max Drawdown 5-Year %
-43.7
Target Price
39.11
P/E
28.19
Forward P/E
11.13
PEG
2.02
P/S
2.26
P/B
4.99
P/Free Cash Flow
39.2
EPS
1.22
Average EPS Est. Cur. Y
2.68
EPS Next Y. (Est.)
3.09
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
8.16
Relative Volume
0.52
Return on Equity vs Sector %
-10
Return on Equity vs Industry %
10.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.08
EBIT Estimation
125.6
Teva Pharmaceutical Industries Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 31173
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
stock quote shares TEVA – Teva Pharmaceutical Industries Limited Stock Price stock today
news today TEVA – Teva Pharmaceutical Industries Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch TEVA – Teva Pharmaceutical Industries Limited yahoo finance google finance
stock history TEVA – Teva Pharmaceutical Industries Limited invest stock market
stock prices TEVA premarket after hours
ticker TEVA fair value insiders trading